Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis

Frontiers in Cellular Neuroscience

Volumn 8, Issue SEP, 2014, Pages

  Michlmayr, Daniela ^a   Lim, Jean K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alphaviruses; Antagonists; Chemokine receptors; Laviviruses; Leukocyte infiltration

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; PLERIXAFOR; REPARIXIN; RS 504393; UNCLASSIFIED DRUG;

APOPTOSIS; ARBOVIRAL ENCEPHALITIS; ARTICLE; CENTRAL NERVOUS SYSTEM; FLAVIVIRUS INFECTION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SEMLIKI FOREST ALPHAVIRUS; SURVIVAL; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS ENCEPHALITIS; WEST NILE VIRUS INFECTION;

EID: 84907667071     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00264     Document Type: Article

References (122)

1. Andrews, D. M., Matthews V. B., Sammels L. M., Carrello A. C., and McMinn P. C. (1999). The severity of Murray Valley encephalitis in mice is linked to neutrophil infiltration and inducible nitric oxide synthase activity in the central nervous system. J. Virol. 73, 8781–8790.
2. Auffray, C., Sieweke M. H., and Geissmann F. (2009). Blood mono-cytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27, 669–692. doi: 10.1146/annurev.immunol.021908. 132557
3. Bachelerie, F., Ben-Baruch A., Burkhardt A. M., Combadiere C., Farber J. M., Graham G. J., etal. (2013). International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66, 1–79. doi: 10.1124/pr.113.007724
4. Bai, F., Kong K. F., Dai J., Qian F., Zhang L., Brown C. R., et al. (2010). A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J. Infect. Dis. 202, 1804–1812. doi: 10.1086/657416
5. Barkhash, A. V., Voevoda M. I., and Romaschenko A. G. (2013). Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population. Antiviral Res. 99, 136–138. doi: 10.1016/j.antiviral.2013.05.008
6. Ben-Nathan, D., Huitinga I., Lustig S., Van Rooijen N., and Kobiler D. (1996). West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch. Virol. 141, 459–469. doi: 10.1007/BF01718310
7. Berger, E. A., Murphy P. M., and Farber J. M. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657–700. doi: 10.1146/annurev.immunol.17.1.657
8. Bhowmick, S., Duseja R., Das S., Appaiahgiri M. B., Vrati S., and Basu A. (2007). Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis. Neurosci. Lett. 414, 45–50. doi: 10.1016/j.neulet.2006. 11.070
9. Bigham, A. W., Buckingham K. J., Husain S., Emond M. J., Bofferding K. M., Gildersleeve H., et al. (2011). Host genetic risk factors for West Nile virus infection and disease progression. PLoS ONE 6:e24745. doi: 10.1371/jour-nal.pone.0024745
10. Bonn, D. (2006). How did chikungunya reach the Indian Ocean? Lancet Infect. Dis. 6:543. doi: 10.1016/S1473-3099(06)70559-X
11. Campbell, G. L., Hills S. L., Fischer M., Jacobson J. A., Hoke C. H., Hombach J. M., et al. (2011). Estimated global incidence of Japanese encephalitis: a systematic review. Bull. World Health Organ. 89, 766–774. doi: 10.2471/BLT.10. 085233
12. Cao, S., Li Y., Ye J., Yang X., Chen L., Liu X., et al. (2011). Japanese encephalitis Virus wild strain infection suppresses dendritic cells maturation and function, and causes the expansion of regulatory T cells. Virol. J. 8:39. doi: 10.1186/1743-422X-8-39
13. Capoccia, B. J., Shepherd R. M., and Link D. C. (2006). G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 108, 2438–2445. doi: 10.1182/blood-2006-04-013755
14. Cardona, A. E., Pioro E. P., Sasse M. E., Kostenko V., Cardona S. M., Dijkstra I. M., et al. (2006). Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9, 917–924. doi: 10.1038/nn1715
15. Carrington, M., Dean M., Martin M. P., and O’Brien S. J. (1999). Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum. Mol. Genet. 8, 1939–1945. doi: 10.1093/hmg/8.10.1939
16. Centers for Disease Control and Prevention [CDC]. (2013). West Nile virus, and other arboviral diseases–United States, 2012. MMWR Morb. Mortal. Wkly. Rep. 62, 513–517.
17. Chapman, R. W., Minnicozzi M., Celly C. S., Phillips J. E., Kung T. T., Hipkin R. W., et al. (2007). A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. Ther. 322, 486–493. doi: 10.1124/jpet.106.119040
18. Chaturvedi, U. C., Mathur A., Tandon P., Natu S. M., Rajvanshi S., and Tandon H. O. (1979). Variable effect on peripheral blood leucocytes during JE virus infection of man. Clin. Exp. Immunol. 38, 492–498.
19. Cheeran, M. C., Hu S., Sheng W. S., Peterson P. K., and Lokensgard J. R. (2003). CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10. J. Virol. 77, 4502–4515. doi: 10.1128/JVI.77.8.4502-4515.2003
20. Cheeran, M. C.-J., Hu S., Sheng W. S., Rashid A., Peterson P. K., and Lokens-gard J. R. (2005). Differential responses of human brain cells to West Nile virus infection. J. Neurovirol. 11, 512–524. doi: 10.1080/13550280500384982
21. Chen, C.-J., Ou Y.-C., Chang C.-Y., Pan H.-C., Liao S.-L., Raung S.-L., et al. (2011). TNF-α and IL-1β mediate Japanese encephalitis virus-induced RANTES gene expression in astrocytes. Neurochem. Int. 58, 234–242. doi: 10.1016/j.neuint.2010.12.009
22. Chung, C.-C., Lee S. S.-J., Chen Y.-S., Tsai H.-C., Wann S.-R., Kao C.-H., et al. (2007). Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature. Infection 35, 30–32. doi: 10.1007/s15010-007-6038-7
23. Cipriani, S., Francisci D., Mencarelli A., Renga B., Schiaroli E., D’Amore C., et al. (2013). Efficacy of CCR5 antagonist maraviroc in reducing the early, ritonavir induced, atherogenesis and the advanced plaque progression in mice. Circulation 127, 2114–2124. doi: 10.1161/CIRCULATIONAHA.113.001278
24. Citro, A., Cantarelli E., Maffi P., Nano R., Melzi R., Mercalli A., et al. (2012). CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J. Clin. Invest. 122, 3647–3651. doi: 10.1172/JCI63089
25. Combadiere, C., Feumi C., Raoul W., Keller N., Rodero M., Pezard A., et al. (2007). CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 117, 2920–2928. doi: 10.1172/JCI31692
26. Deng, H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661–666. doi: 10.1038/381661a0
27. Diamond, M. S., and Gale M. J. (2012). Cell-intrinsic innate immune control of West Nile virus infection. Trends Immunol. 33, 522–530. doi: 10.1016/j.it.2012.05.008
28. Dragic, T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., et al. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667–673. doi: 10.1038/381667a0
29. Du, X., Gustin D. J., Chen X., Duquette J., McGee L. R., Wang Z., et al. (2009). Imidazo-pyrazine derivatives as potent CXCR3 antagonists. Bioorg. Med. Chem. Lett. 19, 5200–5204. doi: 10.1016/j.bmcl.2009.07.021
30. Dwyer, M. P., Yu Y., Chao J., Aki C., Chao J., Biju P., et al. (2006). Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J. Med. Chem. 49, 7603–7606. doi: 10.1021/jm0609622
31. Eash, K. J., Greenbaum A. M., Gopalan P. K., and Link D. C. (2010). CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J. Clin. Invest. 120, 2423–2431. doi: 10.1172/JCI41649
32. Frantz, S. (2005). Drug discovery: playing dirty. Nature 437, 942–943. doi: 10.1038/437942a
33. Fuhrmann, M., Bittner T., Jung C. K. E., Burgold S., Page R. M., Mitteregger G., et al. (2010). Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer’s disease. Nat. Neurosci. 13, 411–413. doi: 10.1038/nn.2511
34. Furuichi, K., Wada T., Iwata Y., Kitagawa K., Kobayashi K.-I., Hashimoto H., et al. (2003). CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J. Am. Soc. Nephrol. 14, 2503–2515. doi: 10.1097/01.ASN.0000089563. 63641.A8
35. Garcia-Tapia, D., Hassett D. E., Mitchell W. J., Johnson G. C., and Kleiboeker S. B. (2007). West Nile virus encephalitis: sequential histopathological and immuno-logical events in a murine model of infection. J. Neurovirol. 13, 130–138. doi: 10.1080/13550280601187185
36. Geissmann, F., Jung S., and Littman D. R. (2003). Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19, 71–82. doi: 10.1016/S1074-7613(03)00174-2
37. Getts, D. R., Terry R. L., Getts M. T., Müller M., Rana S., Shrestha B., et al. (2008). Ly6c+ “inflammatory monocytes” are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J. Exp. Med. 205, 2319–2337. doi: 10.1084/jem.20080421
38. Glass, W. G., Lim J. K., Cholera R., Pletnev A. G., Gao J.-L., and Murphy P. M. (2005). Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202, 1087–1098. doi: 10.1084/jem.20042530
39. Glass, W. G., McDermott D. H., Lim J. K., Lekhong S., Yu S. F., Frank W. A., et al. (2006). CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35–40. doi: 10.1084/jem.20051970
40. Gonsiorek, W., Fan X., Hesk D., Fossetta J., Qiu H., Jakway J., et al. (2007). Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J. Pharmacol. Exp. Ther. 322, 477–485. doi: 10.1124/jpet.106. 118927
41. Gubler, D. J. (1996). The global resurgence of arboviral diseases. Trans. R. Soc. Trop. Med. Hyg. 90, 449–451. doi: 10.1016/S0035-9203(96)90286-2
42. Gupta, N., Lomash V., and Rao P. V. L. (2010). Expression profile of Japanese encephalitis virus induced neuroinflammation and its implication in disease severity. J. Clin. Virol. 49, 4–10. doi: 10.1016/j.jcv.2010.06.009
43. Gupta, N., and Rao P. L. (2011). Transcriptomic profile of host response in Japanese encephalitis virus infection. Virol. J. 8:92. doi: 10.1186/1743-42 2X-8-92
44. Hanefeld, M., Schell E., Gouni-Berthold I., Melichar M., Vesela I., Johnson D., et al. (2012). Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial. J. Diabetes Metab. 3:2. doi: 10.4172/2155-6156.1000225
45. Harrison, J. K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R. K., et al. (1998). Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U.S.A. 95, 10896–10901. doi: 10.1073/pnas.95.18.10896
46. Hayes, E. B., Komar N., Nasci R. S., Montgomery S. P., O’Leary D. R., and Campbell G. L. (2005). Epidemiology and transmission dynamics of West Nile virus disease. Emerg. Infect. Dis 11, 1167–1173. doi: 10.3201/eid1108. 050289a
47. Holub, M., Klucková Z., Beran O., Aster V., and Lobovská A. (2002). Lymphocyte subset numbers in cerebrospinal fluid: comparison of tick-borne encephalitis and neuroborreliosis. Acta Neurol. Scand. 106, 302–308. doi: 10.1034/j.1600-0404.2002.01314.x
48. Horuk, R. (2009). Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 8, 23–33. doi: 10.1038/nrd2734
49. Hosking, M. P., and Lane T. E. (2010). The role of chemokines during viral infection of the CNS. PLoS Pathog. 6, 1–6. doi: 10.1371/journal.ppat. 1000937
50. Hou, C., Singer M., and Matheis M. (2008). “JNJ-17166864, a selective CCR2 antagonist with potential therapeutic implications for inflammatory diseases,” in 104th International Conference American Thoracic Society, Toronto, ON.
51. Hussmann, K. L., and Fredericksen B. L. (2014). Differential induction of CCL5 by pathogenic and non-pathogenic strains of West Nile virus in brain endothelial cells and astrocytes. J. Gen. Virol. 95, 862–867. doi: 10.1099/vir.0. 060558-0
52. Hussmann, K. L., Samuel M. A., Kim K. S., Diamond M. S., and Fredericksen B. L. (2013). Differential replication of pathogenic and nonpathogenic strains of West Nile Virus within astrocytes. J. Virol. 87, 2814–2822. doi: 10.1128/JVI. 02577-12
53. Johnson, R. T., Intralawan P., and Puapanwatton S. (1986). Japanese encephalitis: identification of inflammatory cells in cerebrospinal fluid. Ann. Neurol. 20, 691–695. doi: 10.1002/ana.410200607
54. Jones, K. E., Patel N. G., Levy M. A., Storeygard A., Balk D., Gittleman J. L., et al. (2008). Global trends in emerging infectious diseases. Nature 451, 990–993. doi: 10.1038/nature06536
55. Kindberg, E., Mickienë A., Ax C., Åkerlind B., Vene S., Lindquist L., et al. (2008). A deletion in the chemokine receptor 5 (CCR5)gene is associated with tickborne encephalitis. J. Infect. Dis. 197, 266–269. doi: 10.1086/524709
56. Klein, R. S., Izikson L., Means T., Gibson H. D., Lin E., Sobel R. A., et al. (2004). IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J. Immunol. 172, 550–559. doi: 10.4049/jimmunol.172.1.550
57. Klein, R. S., Lin E., Zhang B., Luster A. D., Tollett J., Samuel M. A., et al. (2005). Neuronal CXCL10 directs CD8+ T-Cell recruitment and control of West Nile Virus Encephalitis. J. Virol. 79, 11457–11466. doi: 10.1128/JVI.79.17.11457-11466.2005
58. Larena, M., Regner M., and Lobigs M. (2012). The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS ONE 7:e44834. doi: 10.1371/journal.pone.0044834.t001
59. Lee, B., Sharron M., Montaner L. J., Weissman D., and Doms R. W. (1999). Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. U.S.A. 96, 5215–5220. doi: 10.1073/pnas.96.9.5215
60. Lepej, S. Ž., Mišicˇ-Majerus L., Jeren T., Rode O. D., Remenar A., Šporec V., et al. (2007). Chemokines CXCL10 and CXCL11 in the cerebrospinal fluid of patients with tick-borne encephalitis. Acta Neurol. Scand. 115, 109–114. doi: 10.1111/j.1600-0404.2006.00726.x
61. Lim, J. K., Glass W. G., McDermott D. H., and Murphy P. M. (2006). CCR5: no longer a“good for nothing”gene – chemokine control of West Nile virus infection. Trends Immunol. 27, 308–312. doi: 10.1016/j.it.2006.05.007
62. Lim, J. K., Louie C. Y., Glaser C., Jean C., Johnson B., Johnson H., et al. (2008). Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197, 262–265. doi: 10.1086/524691
63. Lim, J. K., McDermott D. H., Lisco A., Foster G. A., Krysztof D., Follmann D., et al. (2010). CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J. Infect. Dis. 201, 178–185. doi: 10.1086/649426
64. Lim, J. K., Obara C. J., Rivollier A., Pletnev A. G., Kelsall B. L., and Murphy P. M. (2011). Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J. Immunol. 186, 471–478. doi: 10.4049/jimmunol.1003003
65. Liu, J. S., Amaral T. D., Brosnan C. F., and Lee S. C. (1998). IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J. Immunol. 161, 1989–1996.
66. Loeb, M., Eskandarian S., Rupp M., Fishman N., Gasink L., Patterson J., et al. (2011). Genetic variants and susceptibility to neurological complications following West Nile virus infection. J. Infect. Dis. 204, 1031–1037. doi: 10.1093/infdis/jir493
67. Mack, M., Cihak J., Simonis C., Luckow B., Proudfoot A. E., Plachý J., et al. (2001). Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166, 4697–4704. doi: 10.4049/jimmunol.166. 7.4697
68. Mathur, A., Bharadwaj M., Kulshreshtha R., Rawat S., Jain A., and Chaturvedi U. C. (1988). Immunopathological study of spleen during Japanese encephalitis virus infection in mice. Br. J. Exp. Pathol. 69, 423–432.
69. Mathur, A., Khanna N., and Chaturvedi U. C. (1992). Breakdown of blood–brain barrier by virus-induced cytokine during Japanese encephalitis virus infection. Int. J. Exp. Pathol. 73, 603–611.
70. McCandless, E. E., Piccio L., Woerner B. M., Schmidt R. E., Rubin J. B., Cross A. H., et al. (2008). Pathological expression of CXCL12 at the blood–brain barrier correlates with severity of multiple sclerosis. Am. J. Pathol. 172, 799–808. doi: 10.2353/ajpath.2008.070918
71. McDermott, D. H., Liu Q., Ulrick J., Kwatemaa N., Anaya-O’Brien S., Penzak S. R., et al. (2011). The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 118, 4957–4962. doi: 10.1182/blood-2011-07-368084
72. Metcalf, T. U., Baxter V. K., Nilaratanakul V., and Griffin D. E. (2013). Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis. J. Virol. 87, 2420–2429. doi: 10.1128/JVI.01769-12
73. Michałowska-Wender, G., Losy J., Kondrusik M., Zajkowska J., Pancewicz S., Grygorczuk S., et al. (2006). Evaluation of soluble platelet cell adhesion molecule sPECAM-1 and chemokine MCP-1 (CCL2) concentration in CSF of patients with tick-borne encephalitis. Pol. Merkur. Lekarski 20, 46–48.
74. Michlmayr, D., and McKimmie C. S. (2014). Role of CXCL10 in central nervous system inflammation. Int. J. Interferon Cytokine Mediator Res. 6, 1–18. doi: 10.2147/IJICMR.S35953
75. Michlmayr, D., McKimmie C. S., Pingen M., Haxton B., Mansfield K., Johnson N., et al. (2014). Defining the chemokine basis for leukocyte recruitment during viral encephalitis. J. Virol. 88, 9553–9567. doi: 10.1128/JVI.03421-13
76. Mirzadegan, T., Diehl F., Ebi B., Bhakta S., Polsky I., McCarley D., et al. (2000). Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 275, 25562–25571. doi: 10.1074/jbc.M000 692200
77. Mostashari, F., Bunning M. L., Kitsutani P. T., Singer D. A., Nash D., Cooper M. J., et al. (2001). Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 358, 261–264. doi: 10.1016/S0140-6736(01)05480-0
78. Murphy, P. M. (1997). Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin. Hematol. 34, 311–318.
79. Neumann, H. (2001). Control of glial immune function by neurons. Glia 36, 191–199. doi: 10.1002/glia.1108
80. Ochoa-Callejero, L. L., Pérez-Martínez L. L., Rubio-Mediavilla S. S., Oteo J. A. J., Martínez A. A., and Blanco J. R. J. (2013). Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE 8:e53992. doi: 10.1371/journal.pone.0053992
81. Overington, J. P., Al-Lazikani B., and Hopkins A. L. (2006). How many drug targets are there? Nat. Rev. Drug Discov. 5, 993–996. doi: 10.1038/ nrd2199
82. Palus, M., Vojtíšková J., Salát J., Kopecký J., Grubhoffer L., Lipoldová M., et al. (2013). Mice with different susceptibility to tick-borne encephalitis virus infection show selective neutralizing antibody response and inflammatory reaction in the central nervous system. J. Neuroinflammation 10:77. doi: 10.1186/1742-2094-10-77
83. Parsons, L. M., and Webb H. E. (1982). Virus titres and persistently raised white cell counts in cerebrospinal fluid in mice after peripheral infection with demyeli-nating Semliki Forest virus. Neuropathol. Appl. Neurobiol. 8, 395–401. doi: 10.1111/j.1365-2990.1982.tb00307.x
84. Polianova, M. T., Ruscetti F. W., Pert C. B., and Ruff M. R. (2005). Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res. 67, 83–92. doi: 10.1016/j.antiviral.2005.03.007
85. Purtha, W. E., Chachu K. A., Virgin H. W., and Diamond M. S. (2008). Early B-cell Activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J. Virol. 82, 10964–10974.doi: 10.1128/JVI. 01646-08
86. Ransohoff, R. M., and Engelhardt B. (2012). The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 12, 623–635. doi: 10.1038/nri3265
87. Ransohoff, R. M., Kivisäkk P., and Kidd G. (2003). Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3, 569–581. doi: 10.1038/nri1130
88. Rawal, A., Gavin P. J., and Sturgis C. D. (2006). Cerebrospinal fluid cytology in seasonal epidemic West Nile virus meningo-encephalitis. Diagn. Cytopathol. 34, 127–129. doi: 10.1002/dc.20410
89. Rivest, S. (2009). Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 9, 429–439. doi: 10.1038/nri2565
90. Roth, B. L., Sheffler D. J., and Kroeze W. K. (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353–359. doi: 10.1038/nrd1346
91. Růžek, D., Salát J., Palus M., Gritsun T. S., Gould E. A., Dyková I., et al. (2009). CD8+ T-cells mediate immunopathology in tick-borne encephalitis. Virology 384, 1–6. doi: 10.1016/j.virol.2008.11.023
92. Sambri, V., Capobianchi M., Charrel R., Fyodorova M., Gaibani P., Gould E., et al. (2013). West Nile virus in Europe: emergence, epidemiology, diagnosis, treatment, and prevention. Clin. Microbiol. Infect. 19, 699–704. doi: 10.1111/1469-0691.12211
93. Samuel, M. A., and Diamond M. S. (2005). Alpha/Beta interferon protects against lethal West Nile Virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79, 13350–13361. doi: 10.1128/JVI.79.21.13350-13361.2005
94. Samuel, M. A., and Diamond M. S. (2006). Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80, 9349–9360. doi: 10.1128/JVI.01122-06
95. Semple, B. D., Kossmann T., and Morganti-Kossmann M. C. (2010). Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb. Blood Flow Metab. 30, 459–473. doi: 10.1038/jcbfm.2009.240
96. Serbina, N. V., and Pamer E. G. (2006). Monocyte emigration from bone marrow duringbacterialinfectionrequiressignalsmediatedbychemokinereceptor CCR2. Nat. Immunol. 7, 311–317. doi: 10.1038/ni1309
97. Shi, C., Jia T., Mendez-Ferrer S., Hohl T. M., Serbina N. V., Lipuma L., et al. (2011). Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 34, 590–601. doi: 10.1016/j.immuni.2011.02.016
98. Shirato, K., Kimura T., Mizutani T., Kariwa H., and Takashima I. (2004). Different chemokine expression in lethal and non-lethal murine West Nile virus infection. J. Med. Virol. 74, 507–513. doi: 10.1002/jmv.20205
99. Shrestha, B., Samuel M. A., and Diamond M. S. (2005). CD8+ T cells require perforin to clear West Nile virus from infected neurons. J. Virol. 80, 119–129. doi: 10.1128/JVI.80.1.119-129.2006
100. Singh, A., Kulshreshtha R., and Mathur A. (2000). Secretion of the chemokine interleukin-8 during Japanese encephalitis virus infection. J. Med. Microbiol. 49, 607–612.
101. Sitati, E. M., and Diamond M. S. (2006). CD4+ T-Cell responses are required for clearance of West Nile Virus from the central nervous system. J. Virol. 80, 12060–12069. doi: 10.1128/JVI.01650-06
102. Soriano, S. G., Amaravadi L. S., Wang Y. F., Zhou H., Yu G. X., Tonra J. R., et al. (2002). Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J. Neuroimmunol. 125, 59–65. doi: 10.1016/S0165-5728(02)00033-4
103. Sunnemark, D., Eltayeb S., Nilsson M., Wallstrom E., Lassmann H., Olsson T., et al. (2005). CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligo-dendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J. Neuroinflammation 2:17. doi: 10.1186/1742-2094-2-17
104. Tigabu, B., Juelich T., and Holbrook M. R. (2010). Comparative analysis of immune responses to Russian spring-summer encephalitis and Omsk hemorrhagic fever viruses in mouse models. Virology 408, 57–63. doi: 10.1016/j.virol.2010. 08.021
105. Tobler, L. H., Cameron M. J., Lanteri M. C., Prince H. E., Danesh A., Persad D., et al. (2008). Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. J. Infect. Dis. 198, 979–983. doi: 10.1086/591466
106. Town, T., Jeng D., Alexopoulou L., Tan J., and Flavell R. A. (2006). Microglia recognize double-stranded RNA via TLR3. J. Immunol. 176, 3804–3812. doi: 10.4049/jimmunol.176.6.3804
107. Tsou, C.-L., Peters W., Si Y., Slaymaker S., Aslanian A. M., Weisberg S. P., et al. (2007). Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117, 902–909. doi: 10.1172/JCI29919
108. Tyler, K. L., Pape J., Goody R. J., Corkill M., and Kleinschmidt-DeMasters B. K. (2006). CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology 66, 361–365. doi: 10.1212/01.wnl.0000195890.70898.1f
109. Velasco-Velazquez, M., Jiao X., De La Fuente M., Pestell T. G., Ertel A., Lisanti M. P., et al. (2012). CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72, 3839–3850. doi: 10.1158/0008-5472.CAN-11-3917
110. Wilkin, T. J., and Gulick R. M. (2012). CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu. Rev. Med. 63, 81–93. doi: 10.1146/annurev-med-052010-145454
111. Williamson, J. S., Sykes K. C., and Stohlman S. A. (1991). Characterization of brain-infiltrating mononuclear cells during infection with mouse hepatitis virus strain JHM. J. Neuroimmunol. 32, 199–207. doi: 10.1016/0165-5728(91) 90189-E
112. Winter, P. M., Dung N. M., Loan H. T., Kneen R., Wills B., House D., et al. (2004). Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J. Infect. Dis. 190, 1618–1626. doi: 10.1086/ 423328
113. Yang, Y., Ye J., Yang X., Jiang R., Chen H., and Cao S. (2011). Japanese encephalitis virus infection induces changes of mRNA profile of mouse spleen and brain. Virol. J. 8:80. doi: 10.1186/1743-422X-8-80
114. Yellin, M., Paliienko I., Balanescu A., Ter-Vartanian S., Tseluyko V., Xu L.-A., et al. (2012). A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 64, 1730–1739. doi: 10.1002/ art.34330
115. Zajkowska, J., Moniuszko-Malinowska A., Pancewicz S. A., Muszynska-Mazur A., Kondrusik M., Grygorczuk S., et al. (2011). Evaluation of CXCL10, CXCL11, CXCL12 and CXCL13 chemokines in serum and cerebrospinal fluid in patients with tick borne encephalitis (TBE). Adv. Med. Sci. 56, 311–317. doi: 10.2478/v10039-011-0033-z
116. Zhang, B., Chan Y. K., Lu B., Diamond M. S., and Klein R. S. (2008). CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J. Immunol. 180, 2641–2649. doi: 10.4049/jimmunol.180.4.2641
117. Zhang, B., Patel J., Croyle M., Diamond M. S., and Klein R. S. (2010). TNF-alpha-dependent regulation of CXCR3 expression modulates neuronal survival during West Nile virus encephalitis. J. Neuroimmunol. 224, 28–38. doi: 10.1016/j.jneuroim.2010.05.003
118. Zimmerman, P. A., Buckler-White A., Alkhatib G., Spalding T., Kubofcik J., Combadiere C., et al. (1997). Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3, 23–36.
119. Zlotnik, A., and Yoshie O. (2000). Chemokines: a new classification review system and their role in immunity. Immunity 12, 121–127. doi: 10.1016/S1074-7613(00)80165-X
120. Zlotnik, A., and Yoshie O. (2012). The chemokine superfamily revisited. Immunity 36, 705–716. doi: 10.1016/j.immuni.2012.05.008
121. Zlotnik, A., Yoshie O., and Nomiyama H. (2006). The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 7:243. doi: 10.1186/gb-2006-7-12-243
122. Zujovic, V., Benavides J., Vige X., Carter C., and Taupin V. (2000). Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29, 305–315. doi: 10.1002/(SICI)1098-1136(20000215) 29:4